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 The traditional approach to Pharma clinical trials is to treat the general 
population as a single group.  This has resulted in a large number of failures 
and lost opportunities in bringing new cures to market.  The problem with this 
approach is that most candidate drugs are not effective on 100% of the 
population.  In fact, a good number of drugs that are considered safe on a 
majority of the population are known to have undesirable side-effects on a small 
proportion of the population.  Hence, there is a need for designing clinical trials 
that would identify patient sub-population(s) who are likely to respond 
positively or negatively to a drug. 
ClinicalTrials.gov is an open registry and results database of publicly and 
privately supported clinical studies of human participants conducted around the 
world.  There are public drug information databases such as DrugsAtFDA7 and 
the Canadian DrugBank8 including drug targets.  Next-Generation Sequencing 
(NGS) technologies have made accurate sequencing of human genomes 
affordable.  A good number of genome-wide association studies have been 
published in the recent literature associating specific genomic sequence 
variations with human diseases.  NGS technologies offer a great opportunity to 
repurpose some of those drugs by enabling the identification of the molecular 
basis for the positive and negative effects of these drugs on patients.  Such 
 
7. Drugs@FDA, U.S. FOOD & DRUG ADMIN., http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/ (last visited Jan. 23, 2014). 
8. Open Data Drug & Drug Target Database, DRUGBANK, http://www.drugbank.ca/ (last 
visited Jan. 23, 2014). 
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Pharmacogenomic research can enable proper stratification of patients into 
responders and non-responders.  Clinical trials strategies that take 
pharmacogenomics into account would hence need to be accompanied by 
‘Companion Diagnostic Kits’ to determine whether a patient is likely to 
respond well to a drug.  In order for this to occur faster and become widespread, 
there is a desperate need for the Pharma community to share and have access 
to all completed and ongoing clinical trials data.  Hence, there is a need for 
updating the policies to prevent the withholding of clinical trials data or leaving 
data sharing to individual discretion. 
In the coming decade, a shift in clinical trials design paradigm is likely to 
occur with most trials incorporating a patient stratification strategy as a key 
component in addition to enhancing transparency.  
